Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Pathological features of ALK mutations in Malaysian non-small cell lung cancer (NSCLC) patients

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

ROZIANA Ariffin

Citation

Annals of Oncology (2015) 26 (suppl_9): 8-15. 10.1093/annonc/mdv518

Authors

R.B. Ariffin1, K.A.B. Daud1, A.R.B. Abdul Muttalif2, N.B. Mohd Marzuki2

Author affiliations

  • 1 Genetics, General Hospital Kuala Lumpur, 50586 - Kuala Lumpur/MY
  • 2 Respiratory Medicine, Institute of Respiratory Medicine(Institut Perubatan Respiratori), 50586 - Kuala Lumpur/MY
More

Resources

Aim/Background

We aim to describe the pathological features of ALK positive and negative among Malaysian NSCLC patients.

Methods

This is a retrospective study of 83 NSCLC patients with review of histological features. FISH was performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Vysis ALK Break Apart FISH Probe. Signal interpretation was in accordance with College of American Pathologists guidelines.

Results

Nine patients (11.5%) exhibit ALK rearrangements (excluding the uninterpretable cases) 69 patients were negative and 5 patients were not interpretable. Of the 9 ALK-positive cases, 8 (88.9%) were adenocarcinomas, and 1(11.1%) was squamous cell carcinoma. Age of ALK-positive cases ranges from 33 to 71 years with 5(55.6%) male and 4(44.4%) female. Histology range from moderately to poorly differentiated adenocarcinoma. One case showed Squamous cell carcinoma, one case showed papillary adenocarcinoma with TB pleura.

Conclusions

ALK gene rearrangement was seen in 11.5% and ALK positive patients were relatively younger than negative patients. Histology ranges from moderately to poorly differentiate with one case showing squamous cell carcinoma. For uninterpretable result, test report was relayed to requesting clinicians for repeat testing when possible.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings